| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6176701 | European Urology | 2015 | 10 Pages |
Abstract
We looked for mechanisms related to the progression of PCa in patients undergoing hormonal therapy and treatment with novel drugs targeting the AR. Based on recent data, combining maximal AR inhibition with novel agents targeting other tumor-compensatory, non-AR-related pathways may improve the survival and quality of life of patients with castration-resistant PCa.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Theodoros Karantanos, Christopher P. Evans, Bertrand Tombal, Timothy C. Thompson, Rodolfo Montironi, William B. Isaacs,